Hematologic Oncology | Specialty

FDA Issues CRL for Dasatinib in Chronic Myeloid Leukemia

October 8th 2025

The FDA has issued a CRL for dasatinib, a next-generation formulation of a protein kinase inhibitor, for the treatment of patients with chronic myeloid leukemia.

HyBryte Has an Acceptable Safety Profile in Cutaneous T-Cell Lymphoma

October 7th 2025

A Data Monitoring Committee confirmed that the safety profile of HyBryte is acceptable and that the agent is not associated with safety concerns in CTCL.

FDA Grants Priority Review to Orca-T for Hematologic Malignancies

October 6th 2025

The FDA granted priority review to a biologics license applications seeking the approval of Orca-T for select hematologic malignancies.

The OncFive: Top Oncology Articles for the Week of 9/28

October 4th 2025

The FDA clears maintenance lurbinectedin combination in lung cancer, T-DxD sBLA in HER2-positive breast cancer is accepted for review, and more.

Case Study Showcases Potential Role of Targeted Therapy for Secondary T-Cell Lymphoma After CAR T-Cell Therapy

October 4th 2025

A mogamulizumab-based combination led to complete remission in a patient with CAR-positive T-cell lymphoma with CCR4 overexpression.

Q4 2025: 10 FDA Decisions to Watch in the Realm of Oncology

October 3rd 2025

Here is your Q4 2025 preview spotlighting 10 FDA decisions to watch, including upcoming PDUFAs for belantamab mafodotin, revumenib, sevabertinib, and more.

OncLive Poll Results Spotlight Highly Anticipated Hematology Topics Ahead of ESMO 2025

October 3rd 2025

Multiple myeloma and non-Hodgkin lymphoma emerge as key hematology topics ahead of ESMO 2025, followed by MPNs and T-cell lymphoma.

OncLive’s September Roundup of Key FDA Approvals in Oncology: 4 Decisions to Know

October 3rd 2025

Here is your guide to all therapeutic options that were approved by the FDA in September 2025 spanning tumor types.

OncLive’s September EMA Regulatory Recap: Key EU Approvals in Oncology

October 2nd 2025

Here is your snapshot of all oncologic therapeutic options that were approved by the EMA in September 2025.

Emerging Strategies Aim to Enhance Safety and Monitoring in CAR T-Cell Therapy

October 1st 2025

Samir Parekh, MBBS, discusses monitoring rare CAR T-cell complications, anti-CCR4 therapy, and future research to improve safety and prevent secondary cancers.

Dr Vose on Common Adverse Effects With Epcoritamab in Relapsed/Refractory LBCL

September 30th 2025

Julie M. Vose, MD, MBA, discusses the safety profile of epcoritamab in patients with relapsed/refractory LBCL who have achieved a 2-year complete response.

CCR4-Directed Strategy Achieves Durable Response in T-Cell Lymphoma Following Treatment with Anti-BCMA CAR T-Cell Therapy

September 30th 2025

Samir Parekh, MD, discusses managing a rare T-cell lymphoma post BCMA CAR T-cell therapy and how CCR4-targeted treatment achieved durable remission.

FDA Receives BLA Submission for the Approval of Pivekimab Sunirine for BPDCN

September 30th 2025

The FDA has received a BLA seeking the approval of pivekimab sunirine for the treatment of patients with blastic plasmacytoid dendritic cell neoplasm.

FDA Grants Fast Track Designation to UB-VV111 for R/R B-Cell Malignancies

September 30th 2025

The in vivo CAR T-cell therapy UB-VV111 has received fast track designation from the FDA for the management of relapsed/refractory LBCL and CLL.

Hematologic Oncology Abstracts to Watch at the 2025 ESMO Congress

September 30th 2025

A preview of the hematologic oncology abstracts and presentations to watch at the 2025 ESMO Congress in Berlin.

Poll: Vote on the Top Breast Cancer, Hematology Abstracts to Watch at ESMO 2025

September 29th 2025

Revumenib Joins NCCN Guidelines for NPM1-Mutated R/R Acute Myeloid Leukemia

September 26th 2025

The NCCN has issued a category 2A recommendation for revumenib in relapsed/refractory acute myeloid leukemia harboring an NPM1 mutation.

KITE-363 Shows Potential As a Next-Generation CAR T-Cell Therapy for R/R LBCL

September 26th 2025

Saurabh Dahiya, MD, FACP, discussed how the unique mechanism of action of KITE-363 may improve upon the efficacy of other CAR T-cell therapies for LBCL.

Post–CAR T-Cell Monitoring Optimization Improves Access and Safety for Patients With B-Cell Malignancies

September 23rd 2025

Manali Kamdar, MD, discusses advances with CAR T-cell therapy in B-cell malignancies and the monitoring needs for CRS and ICANS that affect patient access.

CHMP Recommends EU Approval of Subcutaneous Mosunetuzumab in R/R Follicular Lymphoma

September 19th 2025

The CHMP has recommended the European approval of subcutaneous mosunetuzumab in relapsed/refractory follicular lymphoma.